menu
    • menu
    [{"orgOrder":0,"company":"Argenx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argenx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Argenx \/ Undisclosed"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Argenx","sponsor":"OncoVerity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Cusatuzumab","moa":"||CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Argenx \/ OncoVerity","highestDevelopmentStatusID":"8","companyTruncated":"Argenx \/ OncoVerity"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Termination","leadProduct":"Cusatuzumab","moa":"||CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Argenx"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Undisclosed"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cusatuzumab","moa":"CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series A Financing","leadProduct":"Cusatuzumab","moa":"||CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx"},{"orgOrder":0,"company":"OncoVerity","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Series A Financing","leadProduct":"Cusatuzumab","moa":"||CD70 antigen","graph1":"Oncology","graph2":"Phase II","graph3":"OncoVerity","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"OncoVerity \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"OncoVerity \/ Argenx"}]

    Find Clinical Drug Pipeline Developments & Deals for Cusatuzumab

    Menu

    Cusatuzumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML

                            Details : The proceeds will fund Phase 2 of OV-1001 (cusatuzumab), a novel, first-in-class high-affinity monoclonal anti-CD70 antibody, in combination with venetoclax and azacitidine for newly diagnosed AML.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : Cusatuzumab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed...

                            Details : Cusatuzumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Argenx

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Argenx

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : OncoVerity

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief...

                            Details : Under the Licensing Agreement, OncoVerity will optimize JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody, in acute myeloid leukemia (AML) and explore its application in other cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : OncoVerity

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Argenx

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief...

                            Details : The net proceeds will be used for the continued development JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody for the treatment of acute myeloid leukemia (AML).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Argenx

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cu...

                            Details : The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 07, 2021

                            Lead Product(s) : Cusatuzumab,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia o...

                            Details : Cusatuzumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukem...

                            Details : Cusatuzumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 05, 2019

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemi...

                            Details : ARGX-110 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 25, 2017

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Argenx

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Argenx

                            Netherlands arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

                            Details : ARGX-110 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 03, 2016

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            OncoVerity

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ARGX-110 in Participants With Advanced Malignancies

                            Details : ARGX-110 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 19, 2013

                            Lead Product(s) : Cusatuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Argenx | Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth